Sage Journals: Discover world-class research

Abstract

Background: Neutralizing antibodies (NAbs) affect the efficacy of interferon-beta (IFNβ) treatment in multiple sclerosis (MS) patients, particularly if NAbs persist. Persistency depends on NAb titers, which differ between IFNβ preparations.

Objective: This study evaluated IFNβ preparation-specific NAb cut-off titers during early treatment for prediction of NAb persistency.

Methods: Patients who had at least one NAb test between 12 and 30 months (baseline) as well as after more than 48 months (follow-up) on IFNβ treatment were included in this longitudinal study.

Results: At baseline 1064 patients had a NAb test. Of those, 203 had a follow-up test. In the follow-up group 23.2% of patients were NAb positive during baseline. NAb frequency significantly decreased by 40.7% in the IFNβ-1a and by 60% in the IFNβ-1b group at follow-up after a mean time of 75.4 months on treatment, and median NAb titers decreased significantly in both groups. During baseline, NAb titers of >258 neutralizing units (NU) had a sensitivity of 81.3% and a specificity of 90.9% in the IFNβ-1a group, whereas titers of >460 NU had a sensitivity of 100% and a specificity of 91.7% in the IFNβ-1b group to predict persistency at follow-up. When these cut-off titers are applied, 10.2% of all treated patients developed persistent NAbs.

Conclusion: IFNβ preparation-specific NAb cut-off titers for prediction of NAb persistency, which may be useful in individual treatment decision making, are provided.

Keywords

Interferon-beta multiple sclerosis neutralizing antibodies persistency titer

Get full access to this article

View all access options for this article.

References

Deisenhammer

. Neutralizing antibodies to interferon-beta and other immunological treatments for multiple sclerosis: prevalence and impact on outcomes. CNS Drugs 2009; 23: 379–396.

Rudick

Simonian

Alam

. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1998; 50: 1266–1272.

Kappos

Clanet

Sandberg-Wollheim

. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005; 65: 40–47.

Pachner

Cadavid

Wolansky

Skurnick

. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study. Neurology 2009; 73: 1485–1492.

PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001; 56: 1628–1636.

Neutralizing antibodies during treatment of multiple sclerosis with interferon beta-1b: experience during the first three years. The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group. Neurology 1996; 47: 889–894.

Sorensen

Ross

Clemmesen

. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003; 362: 1184–1191.

Gneiss

Reindl

Lutterotti

. Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity. Mult Scler 2004; 10: 507–510.

Sorensen

Koch-Henriksen

Ross

Clemmesen

Bendtzen

. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. Neurology 2005; 65: 33–39.

10.

Herndon

Rudick

Munschauer

3rd . Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis. Mult Scler 2005; 11: 409–419.

11.

Francis

Rice

Alsop

. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005; 65: 48–55.

12.

Rice

Paszner

Oger

Lesaux

Paty

Ebers

. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b. Neurology 1999; 52: 1277–1279.

13.

Polman

Bertolotto

Deisenhammer

. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010; 9: 740–750.

14.

Gneiss

Tripp

Reichartseder

. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult Scler 2006; 12: 731–737.

15.

Millonig

Rudzki

Holzl

. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study. Mult Scler 2009; 15: 977–983.

16.

Gneiss

Reindl

Berger

. Epitope specificity of neutralizing antibodies against IFN-beta. J Interferon Cytokine Res 2004; 24: 283-290.

17.

Brickelmaier

Hochman

Baciu

Chao

Cuervo

Whitty

. ELISA methods for the analysis of antibody responses induced in multiple sclerosis patients treated with recombinant interferon-beta. J Immunol Methods 1999; 227: 121–135.

18.

Gneiss

Tripp

Ehling

. Interferon-beta antibodies have a higher affinity in patients with neutralizing antibodies compared to patients with non-neutralizing antibodies. J Neuroimmunol 2006; 174: 174–179.

19.

Deisenhammer

Reindl

Harvey

Gasse

Dilitz

Berger

. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999; 52: 1239–1243.

20.

Polman

Kappos

White

. Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology 2003; 60: 37–43.

21.

Petkau

White

Ebers

. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler 2004; 10: 126–138.

22.

Kappos

Freedman

Polman

. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370: 389–397.

23.

Frank

Richert

Bash

. Interferon-beta-1b slows progression of atrophy in RRMS: Three-year follow-up in NAb- and NAb+ patients. Neurology 2004; 62: 719–725.

24.

Durelli

Verdun

Barbero

. Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 2002; 359: 1453–1460.

25.

Panitch

Goodin

Francis

. Randomized, comparative study of interferon beta-1a treatment regimens in MS: The EVIDENCE Trial. Neurology 2002; 59: 1496–1506.

26.

Malucchi

Sala

Gilli

. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004; 62: 2031–2037.

27.

Perini

Calabrese

Biasi

Gallo

. The clinical impact of interferon beta antibodies in relapsing-remitting MS. J Neurol 2004; 251: 305–309.

28.

Malucchi

Gilli

Caldano

. Predictive markers for response to interferon therapy in patients with multiple sclerosis. Neurology 2008; 70: 1119–1127.

29.

Clanet

Radue

Kappos

. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology 2002; 59: 1507–1517.

30.

Sominanda

Rot

Suoniemi

Deisenhammer

Hillert

Fogdell-Hahn

. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity. Mult Scler 2007; 13: 208–214.

31.

Farrell

Kapoor

Leary

. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta. Mult Scler 2008; 14: 212–218.

32.

Bertolotto

Malucchi

Milano

Castello

Capobianco

Mutani

. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48: 95–100.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.03 MB

0.12 MB

0.03 MB

Persistency of neutralizing antibodies depends on titer and interferon-beta preparation

Abstract

Keywords

Get full access to this article

References

Supplementary Material